Decreased Levels of Lipoxin A4 and Annexin A1 in Wheezy Infants


GUNGOR H. E. , TAHAN F. , GÖKAHMETOĞLU S. , SARAYMEN B.

INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, cilt.163, sa.3, ss.193-197, 2014 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 163 Konu: 3
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1159/000358490
  • Dergi Adı: INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
  • Sayfa Sayıları: ss.193-197

Özet

Objective: Wheezing is a common and challenging health issue in infancy and early childhood. Asthma diagnosis is frequent in patients with a history of recurrent wheezing. A relationship has been reported between asthma and anti-inflammatory mediators such as lipoxin A4 and annexin A1. However, this remains uncertain in wheezy infants. The aim of the present study was to determine lipoxin A4 and annexin A1 levels in wheezy infants. Materials and Methods: Eighty-seven patients aged 6-36 months were included in this study. Demographic characteristics, clinical features, laboratory data, clinical diagnoses, and treatments, if present, were recorded. Patients were divided into 2 groups: patients with wheezing (n = 59) and healthy controls (n = 28). Blood samples were taken and lipoxin A4 and annexin A1 levels were evaluated by ELISA. Results: Lipoxin A4 and annexin A1 levels were significantly lower in the wheezing group than in the control group (p < 0.05). A significant correlation was found between the serum total immunoglobulin E (IgE) level and the percentage and absolute number of eosinophils (p < 0.05). No significant correlation was found in terms of lipoxin A4 and annexin A1 levels, the serum total IgE level, and the percentage and absolute number of eosinophils among groups (p > 0.05). Conclusion: This is the first study to assess lipoxin A4 and annexin A1 levels in wheezy infants. The levels of lipoxin A4 and annexin A1 were found to be low in wheezy infants. We hope that these results will lead to novel therapeutic options for asthma in cases where an optimal treatment modality is lacking. (C) 20145. Karger AG, Basel